Suchergebnisse - "Tuefferd, M"

PubPharm (9)

1

Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients

enthalten in: Alimentary pharmacology & therapeutics | 2015

von Johansson, S. | Talloen, W. | Tuefferd, M. | +5

2

Evaluation of established human iPSC-derived neurons to model neurodegenerative diseases

enthalten in: Neuroscience | 2015

von Meneghello, G. | Verheyen, A. | Van Ingen, M. | +4

3

Plasma levels of growth‐related oncogene (CXCL1‐3) associated with fibrosis and platelet counts in HCV‐infected patients

enthalten in: Alimentary pharmacology & therapeutics | 2015

von Johansson, S. | Talloen, W. | Tuefferd, M. | +5

4

Evaluation of established human iPSC-derived neurons to model neurodegenerative diseases

enthalten in: Neuroscience | 2015

von Meneghello, G. | Verheyen, A. | Van Ingen, M. | +4

5

Evaluation of established human IPSC-derived neurons to model neurodegenerative diseases

enthalten in: Neuroscience | 2015

von Tuefferd, M. | Van den Wyngaert, I. | Kuijlaars, J. | +4

6

P767 PLASMA LEVELS OF GRO ASSOCIATE WITH FIBROSIS AND PLATELET COUNTS IN HCV INFECTED PATIENTS FROM THE VIRAHEP-C COHORT

enthalten in: Journal of hepatology | 2014

von Johansson, S. | Talloen, W. | Tuefferd, M. | +5

7

P1189 HIGH MIG (CXCL9) PLASMA LEVEL FAVORS RESPONSE TO PEGINTERFERON AND RIBAVIRIN IN HCV INFECTED PATIENTS BUT IS NOT LINKED TO DPP4 ACTIVITY

enthalten in: Journal of hepatology | 2014

von Johansson, S. | Talloen, W. | Tuefferd, M. | +4

8

P1206 ITPA GENE VARIANTS AND ANEMIA DURING TELAPREVIR/PEGINTERFERON/RIBAVIRIN COMBINATION THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION

enthalten in: Journal of hepatology | 2014

von Tuefferd, M. | Palescandolo, E. | Vijgen, L. | +9

9

1167 PRE-TREATMENT IP-10 LEVELS AND IL28B GENOTYPE IN PREDICTION OF SVR IN PRIOR TREATMENT-EXPERIENCED GENOTYPE 1 HCV PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN IN THE REALIZE STUDY

enthalten in: Journal of hepatology | 2012

von Vijgen, L. | Talloen, W. | Scholliers, A. | +9

1
[1]